Check out which companies are making headlines before the bell:
Bed Bath & Beyond–The home goods retailer reported second quarter profit of $1.17 per share, three cents above estimates, with revenue beating consensus as well. The company also issued an upbeat full-year outlook, as promotional activity helped increase store traffic.
Morgan Stanley–The firm's stock was downgraded to "neutral" from "overweight" at JPMorgan Chase. The bank said while it applauds Morgan Stanley's move to restructure its fixed income and commodities unit, returns for that unit are still inadequate.
Wal-Mart–The retailer is teaming with Green Dot to supply checking accounts to customers over 18.
Acorda Therapeutics–The drug maker is buying privately-held Civitas Therapeutics for $525 million in cash. The transaction gives Acorda the rights to a treatment for certain types of Parkinson's disease now in the late stages of development.
Merrimack Pharmaceuticals–The drug maker has announced a development and commercialization agreement with Baxter International for its experimental pancreatic cancer treatment known as MM-398.
Activision Blizzard–The videogame producer will not release its "Titan" multi-player game after all, following years of development. In a statement to CNBC, the company said Titan "just wasn't the game we wanted to make."
Starbucks–The coffee chain will buy the 60.5 percent of its Starbucks Japan affiliate that it didn't already own in a deal valued at $913.5 million. The Japan unit has been operated as a joint venture since 1995.
BlackBerry–The company will release its new "Passport" smartphone today, with launch events scheduled for Toronto, London, and Dubai.
Starz–Starz may be for sale, according to multiple reports. Dow Jones reports that the movie cable channel has retained an investment banking firm to seek a possible buyer, while the LA Times said 21st Century Fox is a possible buyer.
Citizens Financial–The bank priced its initial public offering at $21.50 per share, below the expected range, giving it a value of about $12 billion. Citizens is the U.S. unit of Britain's Royal Bank of Scotland.
Walgreen–The drug chain may sell a majority stake in its infusion services business, according to Reuters, which said such a deal could value the unit at about $1.5 billion.
—By CNBC's Peter Schacknow
Questions? Comments? Email us at marketinsider@cnbc.com